Abstract
(1) Background SeptiCyte RAPID is a molecular test for discriminating sepsis from non-infectious systemic inflammation, and for estimating sepsis probabilities. The objective of this study was the clinical validation of SeptiCyte RAPID, based on testing retrospective banked and prospectively collected patient samples.
(2) Methods The cartridge-based SeptiCyte RAPID test accepts a PAXgene blood RNA sample and provides sample-to-answer processing in ∼1 hour. The test output (SeptiScore, range 0-15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. Retrospective (N=356) and prospective (N=63) samples were tested from adult patients in ICU either having the systemic inflammatory response syndrome (SIRS), or suspected of / diagnosed with sepsis. Patients were clinically evaluated by a panel of three expert physicians blinded to the SeptiCyte test results. Results were interpreted under either the Sepsis-2 or Sepsis-3 framework.
(3) Results Under the Sepsis-2 framework, SeptiCyte RAPID performance for the combined retrospective and prospective cohorts had Area Under the ROC Curve (AUC) ranging from 0.82 to 0.85, negative predictive value 0.91 (sensitivity 0.94) for SeptiScore Band 1 (score range 0.1-5.0; lowest risk of sepsis), and positive predictive value 0.81 (specificity 0.90) for SeptiScore Band 4 (score range 7.4-15; highest risk of sepsis). Performance estimates for the prospective cohort ranged from AUC 0.86-0.95. For physician-adjudicated sepsis cases that were blood culture (+) or blood, urine culture (+)(+), 43/48 (90%) of SeptiCyte scores fell in Bands 3 or 4. In multivariable analysis with up to 14 additional clinical variables, SeptiScore was the most important variable for sepsis diagnosis. Comparable performance was obtained for the majority of patients reanalyzed under the Sepsis-3 definition, although a subgroup of 16 patients was identified that was called septic under Sepsis-2 but not under Sepsis-3.
(4) Conclusions This study validates SeptiCyte RAPID for estimating sepsis probability, under both the Sepsis-2 and Sepsis-3 frameworks, for hospitalized patients on their first day of ICU admission.
Competing Interest Statement
The following coauthors are employees and/or shareholders of Immunexpress: Krupa Navalkar, Thomas D. Yager, Dayle Sampson, James T. Kirk, Silvia Cermelli, Roy F. Davis, Richard B. Brandon
Funding Statement
This study was funded by Immunexpress, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work has been granted by the following ethics committees/IRBs: Amsterdam Medical Center (10-056C), Intermountain Medical Center/Latter Day Saints Hospital (1024931); Johns Hopkins Hospital (IRB00087839); Rush University Medical Center (15111104-IRB01 & 19101603-IRB01); Loyola University Medical Center (208291); Northwell Healthcare (16-02-42-03); Grady Memorial Hospital (000-87806 & 00-115400), Emory University (IRB00115400), University of Southern California Medical Center (HS-19-0884-CR001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Robert_Balk{at}rush.edu (RB); Jared_Greenberg{at}rush.edu (JAG); Mark_A_Yoder{at}rush.edu (MY); gourang_p_patel{at}rush.edu (GP); Georgia; aesper{at}emory.edu (AE); greg.martin{at}emory.edu (GM); jkempke{at}emory.edu (JAK); russmedunc{at}gmail.com; Bert.Lopansri{at}imail.org (BKL); John.burke{at}imail.org (JPB); Mitchell_Levy{at}brown.edu (ML); steven_opal{at}brown.edu (SO); rrothma1{at}jhmi.edu (RER); fdaless2{at}jhmi.edu (FRDA); vsidhay1{at}jhmi.edu (VKS); NEIL.AGGARWAL{at}cuanschutz.edu; EMGILBERT{at}lumc.edu (EG); JPARADA{at}lumc.edu (JPP); mafshar{at}medicine.wisc.edu; t.vanderpoll{at}amsterdamumc.nl (TvdP); marcus.j.schultz{at}gmail.com (MJS); brendon.scicluna{at}um.edu.mt; peterkk{at}live.com; liebler{at}usc.edu (JL); eblodget{at}med.usc.edu (EB); santhi.kumar{at}med.usc.edu (SK); krupa.n{at}immunexpress.com (KN); thomas.y{at}immunexpress.com (TDY); dayle.sampson{at}gmail.com (DS); james.k{at}immunexpress.com (JTK); silvia.c{at}immunexpress.com (SC); roy.d{at}immunexpress.com (RD); richard.b{at}immunexpress.com (RBB)
An improved analysis of the performance of SeptiCyte RAPID under the Sepsis-2 vs. Sepsis-3 frameworks has been conducted. Figure 5 in the previous version has been replaced by Figures 5 & 6 in the current version. The corresponding portions of text in the Results and Discussion sections have been updated accordingly.
Data Availability Statement
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.